sur Nyxoah SA. (isin : BE0974358906)
Nyxoah Presents Promising DREAM Study Data at ISSS 2024
Nyxoah SA revealed significant results from its DREAM study at the ISSS 2024 Educational Update in Miami. The study demonstrated a 71.0% median reduction in Apnea-Hypopnea index (AHI) in patients with Obstructive Sleep Apnea (OSA) 12 months post-treatment.
82.0% of patients showed an AHI below 15, and 67.4% had an AHI below 10. Genio bilateral stimulation indicated a 71.0% reduction in supine AHI and 70.8% across all positions. Secondary endpoints signaled improvements in quality of life and sleepiness.
Chief Investigator Dr. B. Tucker Woodson confirmed the efficacy of Genio, with significant primary and secondary endpoint improvements. CEO Olivier Taelman emphasized the clinical validation of AHI reductions across sleep positions.
Safety results were consistent with other neuromodulation therapies. The DREAM study marks progress towards FDA approval, aiming to make Genio available to OSA patients in the US.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nyxoah SA.